In a real-world setting, omitting secondary staging surgery seems safe in primary incompletely staged patients with a low-risk recurrence profile. We confirmed that FIGO stage, tumor size, and mitotic activity are all significantly associated with the risk of recurrence in incompletely staged patients.
Due et al. (Fri,) studied this question.